These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 21775934)

  • 21. Once-daily highly active antiretroviral therapy for HIV-infected children: safety and efficacy of an efavirenz-containing regimen.
    Scherpbier HJ; Bekker V; Pajkrt D; Jurriaans S; Lange JM; Kuijpers TW
    Pediatrics; 2007 Mar; 119(3):e705-15. PubMed ID: 17308244
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Indinavir plasma concentration and adherence score are codeterminant of early virologic response in HIV-infected patients of the APROCO cohort.
    Duval X; Mentré F; Lamotte C; Chêne G; Spire B; Dellamonica P; Panhard X; Salmon D; Raffi F; Peytavin G; Leport C;
    Ther Drug Monit; 2005 Feb; 27(1):63-70. PubMed ID: 15665749
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Longitudinal Analysis of Daily Pill Burden and Likelihood of Optimal Adherence to Antiretroviral Therapy Among People Living With HIV Who Use Drugs.
    Mohd Salleh NA; Richardson L; Kerr T; Shoveller J; Montaner J; Kamarulzaman A; Milloy MJ
    J Addict Med; 2018; 12(4):308-314. PubMed ID: 29521670
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.
    Ciaffi L; Koulla-Shiro S; Sawadogo AB; Ndour CT; Eymard-Duvernay S; Mbouyap PR; Ayangma L; Zoungrana J; Gueye NFN; Diallo M; Izard S; Bado G; Kane CT; Aghokeng AF; Peeters M; Girard PM; Le Moing V; Reynes J; Delaporte E;
    Lancet HIV; 2017 Sep; 4(9):e384-e392. PubMed ID: 28566227
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Joint longitudinal data analysis in detecting determinants of CD4 cell count change and adherence to highly active antiretroviral therapy at Felege Hiwot Teaching and Specialized Hospital, North-west Ethiopia (Amhara Region).
    Seyoum A; Ndlovu P; Temesgen Z
    AIDS Res Ther; 2017 Mar; 14(1):14. PubMed ID: 28302125
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Influence of prior antiretroviral experience on adherence and responses to new highly active antiretroviral therapy regimens.
    Horberg M; Silverberg M; Hurley L; Delorenze G; Quesenberry C
    AIDS Patient Care STDS; 2008 Apr; 22(4):301-12. PubMed ID: 18338961
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Optimal antiretroviral therapy adherence as evaluated by CASE index score tool is associated with virological suppression in HIV-infected adults in Dakar, Senegal.
    Byabene AK; Fortes-Déguénonvo L; Niang K; Manga MN; Bulabula ANH; Nachega JB; Seydi M
    Trop Med Int Health; 2017 Jun; 22(6):776-782. PubMed ID: 28407436
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Adherence to antiretroviral treatments with a protease inhibitor in HIV-infected patients].
    Salmon-Céron D; Deleuze J; Coste J; Guerin C; Ginsburg C; Blanche P; Finkielsztejn L; Pecqueux L; Chaput S; Gorin I; Sicard D
    Ann Med Interne (Paris); 2000 Jun; 151(4):297-302. PubMed ID: 10922958
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predictors and Evolution of Antiretroviral Therapy Adherence Among Perinatally HIV-Infected Adolescents in Brazil.
    Côté J; Delmas P; de Menezes Succi RC; Galano E; Auger P; Sylvain H; Colson S; Machado DM
    J Adolesc Health; 2016 Sep; 59(3):305-310. PubMed ID: 27320032
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sociodemographic and psychological variables influencing adherence to antiretroviral therapy.
    Gordillo V; del Amo J; Soriano V; González-Lahoz J
    AIDS; 1999 Sep; 13(13):1763-9. PubMed ID: 10509579
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes.
    Palepu A; Tyndall MW; Chan K; Wood E; Montaner JS; Hogg RS
    Antivir Ther; 2004 Oct; 9(5):713-9. PubMed ID: 15535408
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Factors associated with immunovirologic dissociation in HIV-1-infected patients under highly active antiretroviral therapy in the Ambulatory Treatment Center (ATC) in Dakar].
    Kà D; Manga NM; Ngom-Guéye NF; Ndiaga D; Diop M; Cisse-Diallo VMP; Diallo-Mbaye K; Lakhe NA; Fortès-Déguenonvo L; Ndour CT; Diop-Nyafouna SA; Seydi M
    Pan Afr Med J; 2017; 27():16. PubMed ID: 28748017
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HIV-infected ugandan adults taking antiretroviral therapy with CD4 counts >200 cells/μL who discontinue cotrimoxazole prophylaxis have increased risk of malaria and diarrhea.
    Campbell JD; Moore D; Degerman R; Kaharuza F; Were W; Muramuzi E; Odongo G; Wetaka M; Mermin J; Tappero JW
    Clin Infect Dis; 2012 Apr; 54(8):1204-11. PubMed ID: 22423133
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Number of daily pills, dosing schedule, self-reported adherence and health status in 2010: a large cross-sectional study of HIV-infected patients on antiretroviral therapy.
    Gianotti N; Galli L; Bocchiola B; Cahua T; Panzini P; Zandonà D; Salpietro S; Maillard M; Danise A; Pazzi A; Lazzarin A; Castagna A
    HIV Med; 2013 Mar; 14(3):153-60. PubMed ID: 22994659
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predictors of 5-year mortality in HIV-infected adults starting highly active antiretroviral therapy in Thailand.
    Fregonese F; Collins IJ; Jourdain G; Lecoeur S; Cressey TR; Ngo-Giang-Houng N; Banchongkit S; Chutanunta A; Techapornroong M; Lallemant M;
    J Acquir Immune Defic Syndr; 2012 May; 60(1):91-8. PubMed ID: 22293548
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A prospective study of predictors of adherence to combination antiretroviral medication.
    Golin CE; Liu H; Hays RD; Miller LG; Beck CK; Ickovics J; Kaplan AH; Wenger NS
    J Gen Intern Med; 2002 Oct; 17(10):756-65. PubMed ID: 12390551
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Determinants of adherence to highly active antiretroviral therapy among HIV-1-infected patients in Côte d'Ivoire.
    Diabaté S; Alary M; Koffi CK
    AIDS; 2007 Aug; 21(13):1799-803. PubMed ID: 17690579
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Survival and causes of death among HIV-infected patients starting antiretroviral therapy in north-eastern Vietnam.
    Cuong do D; Thorson A; Sönnerborg A; Hoa NP; Chuc NT; Phuc HD; Larsson M
    Scand J Infect Dis; 2012 Mar; 44(3):201-8. PubMed ID: 22122590
    [TBL] [Abstract][Full Text] [Related]  

  • 39. How well do clinicians estimate patients' adherence to combination antiretroviral therapy?
    Miller LG; Liu H; Hays RD; Golin CE; Beck CK; Asch SM; Ma Y; Kaplan AH; Wenger NS
    J Gen Intern Med; 2002 Jan; 17(1):1-11. PubMed ID: 11903770
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of anger in adherence to highly active antiretroviral treatment in patients infected with HIV.
    Leombruni P; Fassino S; Lavagnino L; Orofino G; Morosini P; Picardi A
    Psychother Psychosom; 2009; 78(4):254-7. PubMed ID: 19468260
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.